ALLSTON, Mass., Dec. 11, 2013 (GLOBE NEWSWIRE) -- AB Biosciences, Inc. (ABB) recently received a patent granted by the United States Patent and Trademark Office. US Patent No. 8,530,629 discloses the invention of recombinant antibodies with reduced or eliminated antigen-binding activity using ABB's proprietary CDR-silencing technology. Using the invented antibody in various in vivo and in vitro assays allows researchers to unambiguously distinguish effects that result from specific antigen-antibody interactions from other non-specific antibody effects.
Help employers find you! Check out all the jobs and post your resume.
